SCHEMBL405403

SCHEMBL405403

CC(=O)OCc1cnc(C)c(O)c1CO

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.63
KDM4E B2RXH2 2/20 0.63
ALDH1A1 P00352 2/20 0.63
HSD17B10 Q99714 1/20 0.63
LMNA P02545 3/20 0.50
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
AOX1 Q06278 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
HIF1A Q16665 1/20 0.45
TRIM24 O15164 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
PDXK O00764 2/20 0.42
GAA P10253 1/20 0.39
ESR1 P03372 1/20 0.39
PTGS1 P23219 1/20 0.39
ACP1 P24666 1/20 0.39
PDE4A P27815 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1546086 0.91 KDM4E (0.49) HPGDKDM4EALDH1A1HSD17B10LMNA
Hydrochloric Acid SCHEMBL1546007 0.89 KDM4E (0.47) HPGDKDM4EALDH1A1HSD17B10LMNA
SCHEMBL5346682 0.87 KDM4E (0.61) HPGDKDM4EALDH1A1HSD17B10LMNA
SCHEMBL17145899 0.87 LMNA (0.60) HPGDKDM4EALDH1A1HSD17B10LMNA
SCHEMBL5364590 0.84 KDM4E (0.58) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL3763090 0.83 KDM4E (0.75) HPGDKDM4EALDH1A1HSD17B10LMNA
SCHEMBL1983313 0.83 KDM4E (0.60) HPGDKDM4EALDH1A1HSD17B10LMNA
SCHEMBL11459577 0.82 CA2 (0.41) HPGDKDM4EALDH1A1HSD17B10LMNA
SCHEMBL29906194 0.82 HPGD (0.55) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL23647341 0.81 KDM4E (0.83) HPGDKDM4EALDH1A1HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144747-A1 SYRUP PREPARATION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-05-28 US disclosed
EP-3871655-B1 COMPOSITION FOR ORAL CAVITY SUNSTAR INC (JP) 2026-05-20 EP disclosed
US-12564594-B2 Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-03-03 US disclosed
EP-4606435-A2 PHARMACEUTICAL COMPOSITION COMPRISING POORLY SOLUBLE BASIC AGENT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-08-27 EP disclosed
EP-4316598-B1 PHARMACEUTICAL COMPOSITION COMPRISING A POORLY SOLUBLE BASIC AGENT CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-06-18 EP disclosed
WO-2025053092-A1 CLEANSING COMPOSITION AND METHOD FOR REMOVING AGING ODOR ロート製薬株式会社 2025-03-13 WO disclosed
WO-2025052869-A1 EXTERNAL-USE COMPOSITION AND METHOD FOR ENHANCING FRAGRANCE OF SAME ロート製薬株式会社 2025-03-13 WO disclosed
WO-2024219410-A1 SKIN PERMEATION PROMOTER FOR HYALURONIC ACID, SKIN PERMEATION PROMOTION METHOD FOR HYALURONIC ACID, SKIN PERMEATION INHIBITOR FOR HYALURONIC ACID, AND SKIN PERMEATION INHIBITION METHOD FOR HYALURONIC ACID ロート製薬株式会社 2024-10-24 WO disclosed
EP-4424313-A1 SYRUP PREPARATION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-09-04 EP disclosed
CN-112384223-B Pharmaceutical composition containing poorly soluble basic agent 中外制药株式会社 2024-08-27 CN disclosed
EP-2412367-A1 SOLID PREPARATION Lintec Corporation (JP) 2012-02-01 EP disclosed
EP-2412366-A1 SOLID PREPARATION LINTEC Corporation (JP) 2012-02-01 EP disclosed
US-20120021059-A1 SOLID PREPARATION ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-26 US disclosed
US-20110027326-A1 External Composition for Skin ROHTO PHARMACEUTICAL CO., LTD. (JP) 2011-02-03 US disclosed
EP-2269652-A1 COMPOSITION FOR EXTERNAL APPLICATION TO SKIN Rohto Pharmaceutical Co., Ltd. (JP) 2011-01-05 EP disclosed
US-20100209364-A1 Emulsified Composition ROHTO PHARMACEUTICAL CO., LTD. (JP) 2010-08-19 US disclosed
US-20100021405-A1 EXTERNAL PREPARATION FOR SKIN ROHTO PHARMACEUTICAL CO., LTD. (JP) 2010-01-28 US disclosed
US-20080207560-A1 Composition For External Use ROHTO PHARMACEUTICAL CO., LTD. (JP) 2008-08-28 US disclosed
EP-1849481-A1 COMPOSITION FOR EXTERNAL USE ROHTO PHARMACEUTICAL CO., LTD. (JP) 2007-10-31 EP disclosed
US-20020099032-A1 Preparations and method of producing the same ROHTO PHARMACEUTICAL CO., LTD. (JP) 2002-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12564594-B2 Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile KCNN2, KCNN1, KIT HPGD 2808/4885KDM4E 971/4885ALDH1A1 4665/4885
US-20260144747-A1 SYRUP PREPARATION ALK, IRAK1, IRAK3 HPGD 4611/4885KDM4E 2195/4885ALDH1A1 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.